Dr. Martin Zügel

Member of the Supervisory Board

Dr. Martin Zügel was born on April 6, 1962. After studying medicine in Bochum and Tübingen and molecular biology (MSc) in Amherst, USA, he received his doctorate, Dr. med., in 1989.

Dr. Zügel has more than 20 years of experience in executive positions in the pharmaceutical industry. After working in the hematology and oncology departments of the University Hospital Hamburg-Eppendorf (UKE), he switched to Boehringer Mannheim GmbH (later Hoffmann La Roche AG) in 1991 and joined B. Braun Melsungen AG as a Member of the Board in 2000. In the year 2005, he became part of the pharmaceutical company Merz as CEO of Merz Pharmaceuticals, and starting in 2008, he assumed additionally the role of Spokesperson of Merz GmbH & Co. KGaA. Since his departure from Merz in 2012, Dr. Zügel has acted as Chairman of the Supervisory Board (Glycotope and Amsilk GmbH) and Consultant for various companies in the pharmaceutical and biotech industry as well as Senior Health Care Advisor for the private equity firm CVC Capital Partners.

Since 2015 Dr. Zügel is Chief Executive Officer of Klosterfrau Zürich AG.